Open AccessMonitoring Drug Safety Information - Recommendations of Foreign Regulatory Authorities
Author(s) -
Е. В. Шубникова,
М. А. Дармостукова,
И. И. Снегирева,
Е. О. Журавлева
Publication year - 2020
Publication title -
bezopasnostʹ i risk farmakoterapii
Language(s) - English
Resource type - Journals
eISSN - 2619-1164
pISSN - 2312-7821
DOI - 10.30895/2312-7821-2020-8-1-52-54
Subject(s) - gestodene , medicine , dienogest , desogestrel , cyproterone , pharmacology , flutamide , norethisterone , ethinylestradiol , levonorgestrel , drospirenone , population , antiandrogen , androgen , hormone , family planning , androgen receptor , research methodology , endometriosis , environmental health , prostate cancer , cancer
Analysis of administrative decisions of foreign regulatory authorities on the recoil of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety pro le, conducted by experts of the Scienti c Centre for Expert Evaluation of Medicinal Products revealed 16 administrative decisions. These decisions contained information on the following medicines registered in Russia: norepinephrine, xylometazoline, mometason, liraglutide recombinant, exenatide, insulin recombinant human, insulin degludec, teriparatide, progesterone, gestodene, desogestrel, dienogest, drospirenone, norgestrel, lynestrenol, levonorgestrel, medroxyprogesterone, mestranol, nomegestrol, norethisterone, norgestimate, chlormadinone, cyproterone, estradiol, ethinylestradiol, etonogestrel, ethinylestradiol, nasteride, abiraterone, thiamazole, omega-3-acid ethyl esters, pitavastatin.